These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8394149)
1. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect. Yuen J; Persson I; Bergkvist L; Hoover R; Schairer C; Adami HO Cancer Causes Control; 1993 Jul; 4(4):369-74. PubMed ID: 8394149 [TBL] [Abstract][Full Text] [Related]
2. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Persson I; Yuen J; Bergkvist L; Schairer C Int J Cancer; 1996 Jul; 67(3):327-32. PubMed ID: 8707404 [TBL] [Abstract][Full Text] [Related]
3. Cause-specific mortality in women receiving hormone replacement therapy. Schairer C; Adami HO; Hoover R; Persson I Epidemiology; 1997 Jan; 8(1):59-65. PubMed ID: 9116097 [TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Falkeborn M; Persson I; Terént A; Adami HO; Lithell H; Bergström R Arch Intern Med; 1993 May; 153(10):1201-9. PubMed ID: 8388207 [TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Persson I; Thurfjell E; Bergstrom R; Holmberg L Int J Cancer; 1997 Sep; 72(5):758-61. PubMed ID: 9311590 [TBL] [Abstract][Full Text] [Related]
6. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Nachtigall MJ; Smilen SW; Nachtigall RD; Nachtigall RH; Nachtigall LE Obstet Gynecol; 1992 Nov; 80(5):827-30. PubMed ID: 1328978 [TBL] [Abstract][Full Text] [Related]
7. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Kaufman DW; Palmer JR; de Mouzon J; Rosenberg L; Stolley PD; Warshauer ME; Zauber AG; Shapiro S Am J Epidemiol; 1991 Dec; 134(12):1375-85; discussion 1396-401. PubMed ID: 1663700 [TBL] [Abstract][Full Text] [Related]
8. [Hormone replacement therapy in menopause and risk of breast cancer]. Clavel-Chapelon F; Hill C Presse Med; 2000 Oct; 29(31):1688-93. PubMed ID: 11094609 [TBL] [Abstract][Full Text] [Related]
9. Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older. Thorbjarnardottir T; Olafsdottir EJ; Valdimarsdottir UA; Olafsson O; Tryggvadottir L Acta Oncol; 2014 Jun; 53(6):752-8. PubMed ID: 24460068 [TBL] [Abstract][Full Text] [Related]
10. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657 [TBL] [Abstract][Full Text] [Related]
11. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S; JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697 [TBL] [Abstract][Full Text] [Related]
12. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study. Espié M; Mares P; de Reilhac P; Chevallier T; Daurès JP Gynecol Endocrinol; 2006 Aug; 22(8):423-31. PubMed ID: 17012103 [TBL] [Abstract][Full Text] [Related]
14. Prediagnostic use of hormone therapy and mortality after breast cancer. Newcomb PA; Egan KM; Trentham-Dietz A; Titus-Ernstoff L; Baron JA; Hampton JM; Stampfer MJ; Willett WC Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):864-71. PubMed ID: 18381475 [TBL] [Abstract][Full Text] [Related]
15. The risk of breast cancer after estrogen and estrogen-progestin replacement. Bergkvist L; Adami HO; Persson I; Hoover R; Schairer C N Engl J Med; 1989 Aug; 321(5):293-7. PubMed ID: 2546079 [TBL] [Abstract][Full Text] [Related]
16. Breast cancer incidence and hormone replacement therapy in Canada. De P; Neutel CI; Olivotto I; Morrison H J Natl Cancer Inst; 2010 Oct; 102(19):1489-95. PubMed ID: 20864685 [TBL] [Abstract][Full Text] [Related]
17. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Hulley S; Furberg C; Barrett-Connor E; Cauley J; Grady D; Haskell W; Knopp R; Lowery M; Satterfield S; Schrott H; Vittinghoff E; Hunninghake D; JAMA; 2002 Jul; 288(1):58-66. PubMed ID: 12090863 [TBL] [Abstract][Full Text] [Related]
18. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat. Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153 [TBL] [Abstract][Full Text] [Related]
19. Exogenous progestins and breast cancer. Stanford JL; Thomas DB Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216 [TBL] [Abstract][Full Text] [Related]
20. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Rosenberg LU; Granath F; Dickman PW; Einarsdóttir K; Wedrén S; Persson I; Hall P Breast Cancer Res; 2008; 10(5):R78. PubMed ID: 18803850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]